Dyne Therapeutics (DYN) Net Income (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Net Income of -$262.6 million for Q2 2026, down 140.54% year-over-year from $647.7 million in Q2 2025, and down 49.82% quarter-over-quarter from -$175.3 million in Q1 2026.
Dyne Therapeutics (DYN) Net Income (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Net Income for 8 consecutive years, with -$262.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income fell 140.54% year-over-year to -$262.6 million; the TTM figure through Jun 2026 stood at -$657.2 million (down 53.32% YoY), while the FY2025 annual figure was -$857.6 million, down 41.6% from the prior year.
- Net Income retreated to -$262.6 million in Q2 2026 per DYN's latest filing, from -$175.3 million in the prior quarter.
- Across five years, Net Income topped out at -$62.5 million in Q1 2022 and bottomed at -$262.6 million in Q2 2026.
- Historically, Net Income has averaged -$131.2 million across 5 years, with a median of -$108.7 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income tumbled 193.23% — and 2025, when it jumped 56.35%.
- Dyne Therapeutics' Net Income stood at -$152.4 million in 2022, then sank by 38.9% to -$211.7 million in 2023, then soared by 55.37% to -$94.5 million in 2024, then fell by 17.48% to -$111.0 million in 2025, then slumped by 136.53% to -$262.6 million in 2026.
- Business Quant data shows DYN's Net Income at -$262.6 million in Q2 2026, -$175.3 million in Q1 2026, and -$111.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | -262.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -262.59 Mn |
| Mar 31, 2026 | -175.27 Mn |
| Dec 31, 2025 | -111.02 Mn |
| Sep 30, 2025 | -108.32 Mn |
| Jun 30, 2025 | -109.17 Mn |
| Mar 31, 2025 | -128.69 Mn |
| Dec 31, 2024 | -94.50 Mn |
| Sep 30, 2024 | -96.29 Mn |
| Jun 30, 2024 | -250.09 Mn |
| Mar 31, 2024 | -202.78 Mn |
| Dec 31, 2023 | -211.71 Mn |
| Sep 30, 2023 | -75.59 Mn |
| Jun 30, 2023 | -93.05 Mn |
| Mar 31, 2023 | -77.32 Mn |
| Dec 31, 2022 | -152.43 Mn |
| Sep 30, 2022 | -83.92 Mn |
| Jun 30, 2022 | -66.46 Mn |
| Mar 31, 2022 | -62.52 Mn |
| Dec 31, 2021 | -51.98 Mn |
| Sep 30, 2021 | -103.26 Mn |